Evolva SA   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Reinach Switzerland (2004)
Status: No NME R&D (2004)

Organization Overview

First Clinical Trial
2012
NCT01551381
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Evolva SA

Active Ingredients

Drugs in Phase 3 Trials (2)

Key: Evolva SA (0) Acquired (2)

iclaprim mesylate (3 trials)

linezolid (zyvox) (2 trials)

Drugs in Phase 2 Trials (3)

Key: Evolva SA (1) Acquired (2)

ev-077 (1 trial)

pf-114 (1 trial)

vancomycin (Vancocin) (1 trial)

Drugs in Phase 1 Trials (2)

Key: Evolva SA (0) Acquired (2)

[111in]-fpi-1547 (1 trial)

[225ac]-fpi-1434 (1 trial)

Drugs in Other Trials (1)

resveratrol (3 trials)

Indications

Overview

  • Highest Phase: Phase 2
  • # of Trials: 9
  • # of Trial APIs: 8